文献速递前列腺癌

主动监测前列腺癌患者中追踪活检的价值

Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
PubMed 文献 · J Urol · 2017-07-18

研究比较了MRI-超声融合活检中追踪精确癌灶与常规系统再取样的升级检出率。352例患者在初次活检后6至18个月接受第二次融合活检,总体升级率为25.9%。91例升级中53%仅由追踪活检检出,作者认为追踪功能需进一步研究。

要点

  • 352例主动监测患者第二次活检总体升级率为25.9%(91/352)。
  • Gleason 3+3组升级率26.9%,Gleason 3+4组为22.6%。
  • 91例升级中48例(53%)仅由追踪活检检出。

核心结论

  • 在主动监测的前列腺癌患者中,对特定部位再取样时追踪活检检出升级的频率高于非追踪活检。
  • MRI-超声融合活检的追踪功能需进一步研究。

研究设计与样本

  • 2009年至2017年纳入352例男性,初次MRI-超声融合活检Gleason 3+3者268例、Gleason 3+4者84例。
  • 初次活检所有患者接受12针系统活检,存在MRI可见病灶时加做靶向活检,所有癌灶位置电子记录。
  • 主动监测期间6至18个月后行第二次融合活检,同时获取追踪与非追踪系统样本。
  • 主要结局为随访取样时Gleason评分升高(升级),按活检方法分层。

主要发现

  • 352例中91例(25.9%)在第二次活检时升级,中位间隔11个月。
  • Gleason 3+3组升级率为26.9%,Gleason 3+4组为22.6%。
  • 第二次活检平均取针数:升级组12.2±3.3针,稳定组12.4±4.1针(p无显著差异)。
  • MRI靶点分级0至4级的患者升级率均在约20%至30%(p无显著差异),分级5级者升级率为58.8%。
  • 91例升级中48例(53%)仅由追踪活检检出。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出MRI-超声融合活检的追踪功能需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We compared the upgrading rate obtained by resampling precise spots of prostate cancer (tracking biopsy) vs conventional systematic resampling during followup of men on active surveillance. MATERIALS AND METHODS: From 2009 to 2017 in 352 men prostate cancer was Gleason 3 + 3 in 268 and Gleason 3 + 4 in 84 at initial magnetic resonance imaging-ultrasound fusion biopsy. These men subsequently underwent a second fusion biopsy. At the first biopsy session all men underwent 12-core systematic biopsies and, when magnetic resonance imaging visible lesions were present, targeted biopsies. All cancerous sites were recorded electronically. During active surveillance at a second fusion biopsy session 6 to 18 months later tracking and systematic nontracking samples were obtained. The primary outcome measure was an increase in Gleason score (upgrading) at followup sampling, which was stratified by biopsy method. RESULTS: Overall 91 of the 352 men (25.9%) experienced upgrading at the second biopsy during a median 11-month interval. The upgrade rate in the Gleason 3 + 3 and 3 + 4 groups was 26.9% and 22.6%, respectively. The mean number of cores taken at second biopsy was 12.2 ± 3.3 in men with upgrading and 12.4 ± 4.1 in those who remained stable (p not significant). Men with grade 0 to 4 magnetic resonance imaging targets were all upgraded at approximately the same rate of 20% to 30% (p not significant). However, 58.8% of the men with grade 5 magnetic resonance imaging targets were upgraded. Of the 91 upgrades 48 (53%) were detected only by tracking. CONCLUSIONS: The tracking function of magnetic resonance imaging-ultrasound fusion biopsy warrants further study. When specific sites are resampled in men undergoing active surveillance of prostate cancer, upgrading is detected more often than by nontracking biopsy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chang E, Jones TA, Natarajan S, et al. Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. J Urol. 2017. PMID: 28728993. doi:10.1016/j.juro.2017.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。